CDEC final recommendation: Tiotropium bromide (Spiriva respimat -- Boehringer Ingelheim Canada Ltd.) indication : chronic obstructive pulmonary disease
The Canadian Drug Expert Committee (CDEC) recommends that tiotropium bromide (Spiriva Respimat) be listed for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphys...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, July 16, 2015
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The Canadian Drug Expert Committee (CDEC) recommends that tiotropium bromide (Spiriva Respimat) be listed for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for the reduction of exacerbations |
|---|---|
| Physical Description: | 1 PDF file (7 pages) |